BIIBBiogen

$225.73+57% 1Y

$225.73

$135.6752 weeks$228.71

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in and cheap vs its sector, but at the top of its own P/E range.

2 good, 1 to watch

What the price assumes~−1% a year

Priced for a decline (~−1% a year). Little growth is priced in even as revenue fell 1% a year over three years, potential value, or a value trap.

Vs its own P/E rangedearer than 83% of its own historyderived

Expensive vs its own history: P/E 24.3 vs a 16.1 median over 40 quarters (+50% vs median).

Vs sector (EV/EBIT)19.1×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Mar 31, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldbetter than 78% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What BIIB's price assumes

Biogen trades at 24.3× earnings against 26.2× for the median Drug Manufacturers - General name, cheaper than its own group.

24.3

Trailing P/E · Drug Manufacturers - General median 26.2 · cheaper than the typical name in its group

Price / sales: 2.92
Price / sales · today's price, trailing year to Mar 31, 2026
Free cash flow yield: 8.3%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: −1.2%
Growth the price implies · The price pays for −1.2% free cash flow growth a year for a decade; the business has delivered +19% a year over the last three.

Details›

Price / booktoday's price, trailing year to Mar 31, 2026: 1.56
EV / EBITtoday's price, trailing year to Mar 31, 2026: 19.1
EV / salestoday's price, trailing year to Mar 31, 2026: 3.12
Healthcare median P/E509 names: 26.2
Drug Manufacturers - General median P/E16 names: 26.2
Free cash flow, trailing twelve months: $2.42B
Market capitalisation: $29.0B
3-year revenue growth: −0.55%
3-year free cash flow growth: +19%

What the market has paid for these earnings: 40 quarters of its own multiple × $9.30 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$119.68
Its own P/E history, median	$150.00
Its own P/E history, upper quartile	$193.59
52-week range	$135.67 – $228.71
Today	$225.73

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Cheap stocks by free cash flow yield

Drug Manufacturers, General

The closest names by size in the same industry